We are live on
!
Find out more
RJA
Robshaw & Julian Associates Portfolio holdings
AUM
$140M
1-Year Est. Return
13.69%
This Fund
S&P 500
This Quarter
Est. Return
+0.1%
1 Year Est. Return
+13.69%
3 Year Est. Return
+19.35%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$130M
AUM Growth
+$8.8M
(+7.3%)
Cap. Flow
+$8.26M
Cap. Flow
% of AUM
6.37%
Top 10 Holdings %
Top 10 Hldgs %
42%
Holding
43
New
3
Increased
27
Reduced
5
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard FTSE Europe ETF
VGK
|
+$4.05M |
| 2 |
SDRL
Seadrill Limited Common Stock
SDRL
|
+$1.63M |
| 3 |
Gilead Sciences
GILD
|
+$1.48M |
| 4 |
JPMorgan Chase
JPM
|
+$698K |
| 5 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$479K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$2.37M |
| 2 |
SPDR Gold Trust
GLD
|
+$1.12M |
| 3 |
Nucor
NUE
|
+$770K |
| 4 |
Procter & Gamble
PG
|
+$523K |
| 5 |
RTX Corp
RTX
|
+$260K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.01% |
| 2 | Energy | 13.3% |
| 3 | Healthcare | 12.79% |
| 4 | Financials | 10.98% |
| 5 | Industrials | 10.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Microsoft
MSFT
$3.71T
| $2.1M | 1.62% |
51,350
+2,150
| +4% | +$80.7K |
|
27
D.R. Horton
DHI
$42.3B
| $1.89M | 1.46% |
87,350
+800
| +0.9% | +$18.1K |
|
|
SDRL
28
DELISTED
Seadrill Limited Common Stock
SDRL
| $1.56M | 1.2% |
+166
| New | +$1.63M |
|
|
29
State Street SPDR S&P 500 ETF Trust
SPY
$810B
| $1.53M | 1.18% |
20,885
+2,610
| +14% | +$479K |
|
|
PX
30
DELISTED
Praxair Inc
PX
| $1.52M | 1.17% |
11,594
+1,725
| +17% | +$224K |
|
|
31
Gilead Sciences
GILD
$165B
| $1.34M | 1.03% |
+18,880
| New | +$1.48M |
|
32
Coca-Cola
KO
$375B
| $1.34M | 1.03% |
34,600
| – | – |
|
33
Vanguard Materials ETF
VAW
$3.08B
| $1.19M | 0.92% |
11,235
+845
| +8% | +$87K |
|
|
DD
34
DELISTED
Du Pont De Nemours E I
DD
| $1.01M | 0.78% |
15,795
-211
| -1% | -$12.9K |
|
35
3M
MMM
$94.3B
| $543K | 0.42% |
4,784
| – | – |
|
36
Bristol-Myers Squibb
BMY
$132B
| $520K | 0.4% |
10,000
| – | – |
|
37
AT&T
T
$163B
| $436K | 0.34% |
16,447
| – | – |
|
|
38
SPDR Gold Trust
GLD
$142B
| – | – |
-9,640
| Closed | -$1.12M |
|
|
39
Nucor
NUE
$62.1B
| – | – |
-14,425
| Closed | -$770K |
|
|
40
Procter & Gamble
PG
$339B
| – | – |
-6,425
| Closed | -$523K |
|
|
41
Teva Pharmaceuticals
TEVA
$41.2B
| – | – |
-59,103
| Closed | -$2.37M |
|
Similar funds
BCM
BJCM
RP
ACPVT
SFA
KL
KFS
FHC
Robshaw & Julian Associates's Q1 2014 Portfolio in Review
As of Q1 2014, Robshaw & Julian Associates held 43 positions worth $130M, up 7.3% from $121M the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Robshaw & Julian Associates deployed $8.26M of net new capital in Q1 2014, opening 3 new positions and adding to 27 existing holdings. Its largest new stake was Vanguard FTSE Europe ETF: 69,300 shares worth $4.08M.
By sector, the portfolio is most concentrated in Technology at 17% of assets, down from 18% a quarter earlier, followed by Energy and Healthcare.
On the sell side, the largest reduction was RTX Corp, an estimated $260K trimmed.
- Robshaw & Julian Associates's largest Q1 2014 buy was Vanguard FTSE Europe ETF: 69,300 shares worth $4.08M.
- Robshaw & Julian Associates added most to JPMorgan Chase in Q1 2014, an estimated $698K increase.
- Robshaw & Julian Associates's biggest Q1 2014 reduction was RTX Corp, cutting an estimated $260K.
- Robshaw & Julian Associates fully exited Teva Pharmaceuticals in Q1 2014, selling an estimated $2.37M.
- Robshaw & Julian Associates's ten largest holdings make up 42% of its $130M portfolio in Q1 2014.
- Robshaw & Julian Associates opened 3 new positions and closed 4 in Q1 2014.
- Robshaw & Julian Associates's portfolio value rose 7.3% quarter-over-quarter to $130M.
Based on Robshaw & Julian Associates's 13F filing for Q1 2014, filed 5 May 2014.